Précédent|Prochain

Traitement différencié de l'insuffisance cardiaque chronique basé sur la théorie « suivre son Qi est harmonie, contrevenir à son Qi est maladie »

  • role： First author第一作者
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM），Shenyang 110847，China

  • Email：120168967@qq.com
  • Introduction：刘宗一，在读博士，主治医师，从事中西医结合心血管疾病研究，E-mail：120168967@qq.com
LIU Zongyi1,  
  • role： Corresponding author通信作者
  • Affiliation：

    The Affiliated Hospital of Liaoning University of TCM，Shenyang 110000，China

  • Email：yanzhang1016@126.com
  • Introduction：张艳，博士，博士生导师，主任医师，从事中西医结合心血管疾病研究，E-mail：yanzhang1016@126.com
ZHANG Yan2*,  
  • Affiliation：

    Liaoning University of Traditional Chinese Medicine（TCM），Shenyang 110847，China

CUI Hongyu1

résumé

L'insuffisance cardiaque chronique (ICC) est le stade terminal de diverses maladies cardiaques. Selon la médecine traditionnelle chinoise, la pathogenèse de l'ICC repose sur un vide de la racine et un excès des symptômes externes ; ce vide se caractérise principalement par une insuffisance de l'énergie du cœur (Qi du cœur), tandis que l'excès correspond à une accumulation excessive de produits pathologiques tels que le mucus, la stase et la rétention d'eau. Dans le processus de survenue et de développement de l'ICC, la perturbation du Qi du cœur reste la clé de la maladie. Dans le 《Huangdi Neijing · Suwen · Chapitre sur les Cinq Mouvements et Grande Théorie》, il est dit : « Suivre son Qi est harmonie, contrevenir à son Qi est maladie », ce qui exprime la relation entre le corps humain et le Qi de la nature. L'harmonie signifie santé, la contrariété maladie. Ce principe s'applique également à l'intérieur du corps humain, où l'harmonie entre les organes et leur Qi assure la santé, et la contrariété entraîne la maladie. La survenue de l'ICC et la relation entre le cœur et son Qi suivent ce même principe. Cet article part de cette théorie pour analyser le lien entre « contrevenir à son Qi » et les maladies humaines ; il analyse ensuite le « suivre » et « contrevenir » au Qi du cœur, jusqu'à la pathogenèse de l'ICC. Il explore la correspondance entre le Qi du cœur et la physiologie moderne dans l'état de « suivre son Qi », ainsi que la correspondance entre le Qi du cœur et la pathologie moderne dans l'état de « contrevenir à son Qi », ainsi que la relation entre « contrevenir à son Qi » et les différentes phases de l'ICC. Enfin, il propose, selon le point de vue « contrevenir à son Qi entraîne la maladie », un traitement de l'ICC visant : d'une part à nourrir l'insuffisance du Qi du cœur (tonifier le Qi du cœur, en même temps renforcer la rate), d'autre part à libérer les voies du Qi du cœur (transformer le mucus, éliminer les impuretés pour libérer les voies, dissiper la stase et ouvrir les méridiens pour faciliter la circulation sanguine, transformer les liquides et chasser l'eau pour faciliter la circulation). L'article analyse aussi l'effet des médicaments chinois simples et des formules sur le myocarde et les indices microscopiques du corps sous les méthodes « nourrir » et « libérer ». Par ces traitements, le Qi du cœur retrouve ses propriétés de « plénitude » et de « libre circulation », permettant l'harmonie du Qi du cœur et une amélioration de l'ICC. On espère que cette approche offrira une nouvelle perspective pour le traitement de l'ICC à l'avenir.

mots-clés

insuffisance cardiaque chronique;Qi du cœur;suivre son Qi est harmonie;contrevenir à son Qi est maladie;médicine traditionnelle chinoise

References

  1. 1.
    WANG H，SHI J J，SHI S Q，et al.Bibliometric analysis on the progress of chronic heart failure［J］.Curr Probl Cardiol，2022，47（9）：101213.
  2. 2.
    KONG J J，LIU P，DAI X H.Data mining and clinical efficacy of Qi-tonifying and blood-activating therapy in treatment of chronic heart failure［J］.World Chin Med，2024，19（17）：2663-2669.
  3. 3.
    SCHWINGER R H G.Pathophysiology of heart failure［J］.Cardiovasc Diagn Ther，2021，11（1）：263-276.
  4. 4.
    MASCOLO A，DI MAURO G，CAPPETTA D，et al.Current and future therapeutic perspective in chronic heart failure［J］.Pharmacol Res，2021，175：106035.
  5. 5.
    LUO J Q，DENG Z W，LI T D，et al.A review on the progress in the treatment of heart failure［J］.J Pract Med，2022，38（10）：1181-1186.
  6. 6.
    MA R Q，YANG Z Q，KOU J P，et al.Analysis on new research and development ideas and technical points of traditional Chinese medicine for prevention and treatment of chronic heart failure［J］.China J Chin Mater Med，2020，45（11）：2720-2724.
  7. 7.
    MAO J Y，ZHAO Z Q，WANG X L.Current study of the treatment for heart failure with traditional Chinese and western medicine［J］.Chin J Pract Intern Med，2020，40（12）：1001-1004.
  8. 8.
    MARIN W，MARIN D，AO X，et al.Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury［J］.Int J Mol Med，2021，47（2）：485-499.
  9. 9.
    MORALES P E，ARIAS-DURáN C，ÁVALOS-GUAJARDO Y，et al.Emerging role of mitophagy in cardiovascular physiology and pathology［J］.Mol Aspects Med，2020，71：100822.
  10. 10.
    WANG K Y，LIU C W，ZHANG H.Advances in the study of calcium circulatory abnormalities and cardiovascular disease［J］.Chin J Cardiovasc Res，2025，23（1）：74-78.
  11. 11.
    DENG J L，JIANG Y Q，CHEN Z B，et al.Mitochondrial dysfunction in cardiac arrhythmias［J］.Cells，2023，12（5）：679.
  12. 12.
    LAI L，QIU H Y.The physiological and pathological roles of mitochondrial calcium uptake in heart［J］.Int J Mol Sci，2020，21（20）：7689.
  13. 13.
    GALLO G，SAVOIA C，GALLO G，et al.New insights into endothelial dysfunction in cardiometabolic diseases：Potential mechanisms and clinical implications［J］.Int J Mol Sci，2024，25（5）：2973.
  14. 14.
    HINTON A，CLAYPOOL S M，NEIKIRK K，et al.Mitochondrial structure and function in human heart failure［J］.Circ Res，2024，135（2）：372-396.
  15. 15.
    SABBAH H N.Targeting the mitochondria in heart failure：A translational perspective［J］.JACC Basic Transl Sci，2020，5（1）：88-106.
  16. 16.
    WU C N，ZHANG Z，ZHANG W D，et al.Mitochondrial dysfunction and mitochondrial therapies in heart failure［J］.Pharmacol Res，2022，175：106038.
  17. 17.
    LI A L，LIAN L，CHEN X N，et al.The role of mitochondria in myocardial damage caused by energy metabolism disorders：From mechanisms to therapeutics［J］.Free Radic Biol Med，2023，208：236-251.
  18. 18.
    XIE K，LI C，WANG Y，et al.Exploring theoretical connotation of "heart affected by spleen Qi" based on "spleen-mitochondria-heart" axis of heart failure［J］.Chin Arch Tradit Chin Med，2024，42（10）：118-122.
  19. 19.
    LIU P，YU Y F，YANG X Y，et al.Inflammatory mechanism of coronary heart disease and intervention strategies of Chinese medicine based on ''phlegm，stasis，toxin'' theory［J］.Chin J Exp Tradit Med Form，2023，29（12）：185-191.
  20. 20.
    LIU X L，LIU Y，WANG Y，et al.Essence analysis of objective indicators related to phlegm syndrome based on multivariate statistics［J］.Liaoning J Tradit Chin Med，2020，47（5）：8-12.
  21. 21.
    ZHONG S J，LI J，WANG L J，et al.Research advances in mechanism of lipid infiltration of coronary heart disease and simultaneous treatment of phlegm and blood stasis based on phlegm-blood stasis correlation theory［J］.China J Chin Mater Med，2023，48（6）：1431-1437.
  22. 22.
    JI X L.Analysis of the concept of "Yin" and "phlegm"，and the clinical significance and research ideas on pathogenic factors of Yin［J］.J Beijing Univ Tradit Chin Med，2022，45（5）：513-518.
  23. 23.
    ABASSI Z，KHOURY E E，KARRAM T，et al.Edema formation in congestive heart failure and the underlying mechanisms［J］.Front Cardiovasc Med，2022，9：933215.
  24. 24.
    PANG L L，LI Z，WANG Y，et al.Research overview of treating dyslipidemia by invigorating the spleen to eliminate phlegm［J］.World Chin Med，2024，19（8）：1209-1214.
  25. 25.
    ZHAO F Y，GUO X P，MENG Y，et al.HUANG Lijuan's experience in treating chronic heart failure in stages［J］.China J Tradit Chin Med Pharm，2021，36（5）：2746-2749.
  26. 26.
    HE H L，WANG Y J，HAN Y T，et al.Professor XIE Liandi's experience in differentiating and treating chronic heart failure based on the combination of disease and syndrome［J］.Mod J Integr Tradit Chin West Med，2024，33（18）：2547-2551，2562.
  27. 27.
    JIN X Y，ZHANG J H，ZHANG L S，et al.ZHANG Boli's experience in the stage-based diagnosis and treatment of chronic heart failure［J］.J Tradit Chin Med，2018，59（19）：1633-1636.
  28. 28.
    WANG Y N，SUN Y L，HUANG P P，et al.Clinical study on Yiqi Yangyin decoction combined with routine therapy for chronic heart failure in stable stage［J］.J New Chin Med，2022，54（11）：71-75.
  29. 29.
    LU H，DENG H，WANG C，et al.Characteristics of cardiopulmonary function，exercise endurance，and the levels of NT-proBNP and TNT in elderly patients with stable chronic heart failure［J］.Pract Geriatr，2023，37（11）：1138-1142.
  30. 30.
    LI J P，HUANG X M.CUI Decheng's experience in treating the stable phase of chronic heart failure from the perspective of the spleen and stomach［J］.Inner Mongolia J Tradit Chin Med，2024，43（5）：91-93.
  31. 31.
    ZHOU J X.Exploring the clinical effect of recombinant human brain natriuretic peptide in treating patients with acute exacerbation of chronic heart failure［J］.China Foreign Med Treat，2024，43（1）：102-105.
  32. 32.
    WANG Q，LUO S H，HANG K L，et al.A summary of using traditional Chinese medicine combined with abdominal acupuncture in the remission stage of chronic heart failure based on the syndrome of deficiency of heart，spleen and Qi，and the retention of phlegm，blood stasis and water dampness［J］.Jiangsu J Tradit Chin Med，2022，54（12）：49-52.
  33. 33.
    CHEN Y F，HUANG Y Z.Study on the cause of anorexia and its correlation with prognosis in patients with chronic heart failure［J］.Jilin Med J，2018，39（3）：429-430.
  34. 34.
    JIANG T W，TIAN Z Y，WEN N Y，et al.Research progress on ginsenosides involved in regulating energy metabolism disorder［J］.Chin Arch Tradit Chin Med，2021，39（5）：5-8.
  35. 35.
    ZHAO R R，HOU Y L，LI M H，et al.Effect of ginsenoside compound K on cardiac mitochondrial function in sepsis［J］.Lishizhen Med Mater Med Res，2024，35（3）：550-553.
  36. 36.
    FAN Z J，XIE L D，DONG Q Z，et al.Astragalus polysaccharides （APS） protects against myocardial ischemia-reperfusion （I/R） injury through mitochondrial mechanisms［J］.J Basic Chin Med，2017，23（4）：484-487.
  37. 37.
    WANG Z F.Effect of radix codonopsis on the anti-oxidation ability of myocardial mitochondria in rats with high-intensity and endurance training［J］.Jiangsu Med J，2011，37（13）：1515-1516.
  38. 38.
    WEN J X，ZHAO Y L.Study on improvement effects of Zingiber officinale decoction on mitochondrial function injury of cardiomyocytes［J］.China Pharm，2021，32（9）：1070-1076.
  39. 39.
    WANG X L，LI B，XIE S Y，et al.Effects of Shenfu Yixin decoction on cardiac function and the related factors of energy metabolism in heart failure rats after myocardial infarction［J］.China J Tradit Chin Med Pharm，2021，36（5）：2521-2525.
  40. 40.
    LI T T，GUO Y J，REN J，et al.Danggui Buxue decoction improves heart function of chronic intermittent hypoxia mice by promoting mitochondrial autophagy and inhibiting cardiomyocyte apoptosis［J］.China J Chin Mater Med，2022，47（11）：3066-3072.
  41. 41.
    PANG Y，LU J Q，TANG M L，et al.Effects of Qiangxin decoction on reactive oxygen species in infarcted myocardial area tissue and PINK1/Parkin - mediated mitophagy in rats with chronic heart failure model［J］.J Tradit Chin Med，2023，64（7）：722-728.
  42. 42.
    PANG Y，MAO M L，LU J Q，et al.Effects of Qiangxin decoction on myocardial mitochondrial homeostasis and energy metabolism in chronic heart failure rats［J］.China Pharm，2024，35（15）：1831-1836.
  43. 43.
    SONG Y Y，CUI L，HE Y F，et al.Effect of Shenfu Yixin granules on mitochondrial dynamics in rats with heart failure after myocardial infarction［J］.Chin J Exp Tradit Med Form，2024，30（11）：87-94.
  44. 44.
    CHEN Q，FU Y F，LIU H T，et al.Study on the effects of Chenpi total flavonoids on GAGs metabolism in vascular smooth muscle cells［J］.Tradit Chin Drug Res Clin Pharmacol，2019，30（2）：179-183.
  45. 45.
    HUANG X B，CHEN J S，WU T M，et al.Mechanism of Perilla oil's intervention in vascular endothelial cell miR-21 targeted regulation of MMP-9［J］.J Xi'an Jiaotong Univ Med Sci：Med Edi，2016，37（1）：123-127.
  46. 46.
    QIU Y.Efficacy of modified Gualou Xiebai Banxia decoction in the treatment of elderly coronary heart disease patients with obstruction of phlegm turbidity syndrome［J］.Chin Health Care，2024，42（14）：12-15.
  47. 47.
    WANG Y Q，SHUI D，WANG X Y.Comparative study on the anti-hyperlipidemia effects of Gualou Xiebai categorized formula based on HepG2 cells and zebrafish model［J］.Chin J Hosp Pharm，2022，42（5）：495-500.
  48. 48.
    CHEN W H，MENG W S，LI H，et al.Effect of Gualou Xiebai Banxia decoction on myocardial microangiogenesis and HIF-1α/VEGF-related pathways in myocardial ischemia model rats［J］.Chin J Exp Tradit Med Form，2024，30（17）：1-9.
  49. 49.
    YUAN Q Y，GAN X，BAO H G，et al.Effects of Zhishi Xiebai Guizhi decoction on serum inflammatory factors and vascular endothelial function in patients with unstable angina pectoris［J］.China J Tradit Chin Med Pharm，2021，36（11）：6893-6897.
  50. 50.
    FAN K T，DAI X D，YAN H F，et al.Medication rule of TCM treatment of platelet aggregation［J］.Liaoning J Tradit Chin Med，2017，44（5）：1014-1018.
  51. 51.
    ZHANG Y W，ZHANG D S，JING Y S.Research progress on the mechanism of Danshensu in protecting vascular endothelial cells from oxidative damage［J］.Chin J Pharmacol Toxicol，2021，35（10）：806.
  52. 52.
    ZHANG Y F，DU M，WANG J R，et al.Tanshinone ⅡA promotes reverse cholesterol transport and improves atherosclerosis［J］.Chin Pharmacol Bull，2023，39（10）：1835-1839.
  53. 53.
    LIU J G，ZHANG D W，LIU Y Y，et al.Separation of extracts from Chuanxiong rhizoma and the pharmacological effects on myocardium of ischemia/reperfusion injury in rats［J］.Chin J Mod Appl Pharm，2019，36（19）：2369-2375.
  54. 54.
    WEI E T，ZHANG Q.Effect and mechanism of ligustrazine on atherosclerosis［J］.Lishizhen Med Mater Med Res，2019，30（5）：1192-1194.
  55. 55.
    YANG W C，WANG X P，BAI J Q.Impact on Salvia miltiorrhiza-Carthamus tinctorius ratio on hemorheology and hemodynamics of acute blood stasis rats［J］.J Northwest A F Univ：Nat Sci Edi，2015，43（12）：35-40.
  56. 56.
    ZHANG W，LIU X D，LI F，et al.Research on Xuefu Zhuyu decoction regulating endothelial progenitor cells to repair damaged vascular endothelium［J］.Chin Pharmacol Bull，2016，32（3）：427-433.
  57. 57.
    LIU Q J，XU X X.To observe the clinical efficacy of modified Danshen decoction combined with Xuefu Zhuyu decoction plus western medicine in the treatment of patients with coronary heart disease complicated by heart failure of Qi stagnation and blood stasis type［J］.Prev Treat Cardiovasc Dis，2023，13（34）：6-11.
  58. 58.
    ZHANG Y K，FENG Y N，BIAN J Q，et al.Effects and mechanism of Danshen decoction on physiological characteristics and function of platelet in hyperlipidemia model rats［J］.China Pharm，2023，34（7）：790-795.
  59. 59.
    GUO Y D，HU Y C，CAO C R，et al.Bioassay method for compound Danshen tablets based on a platelet aggregation inhibition test［J］.Acta Pharm Sin，2019，54（12）：2184-2188.
  60. 60.
    ZHANG M H，ZHANG T，GUO S，et al.Protective effect of compound Danshen tablets on hyperlipidemic rats by regulating LKB1-AMPK signal pathway［J］.Tradit Chin Drug Res Clin Pharmacol，2022，33（2）：158-164.
  61. 61.
    HU G S，HUANG C G，ZHANG Y，et al.Accumulation of biomass and four triterpenoids in two-stage cultured Poria cocos mycelia and diuretic activity in rats［J］.Chin J Nat Med，2017，15（4）：265-270.
  62. 62.
    WU Z L，REN H，LAI W Y，et al.Sclederma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure［J］.J Ethnopharmacol，2014，155（1）：563-571.
  63. 63.
    YAN L，OU Z M，WANG Y，et al.Mechanism of Alismatis Rhizoma and its processed product against edema of kidney Yin deficiency in rats［J］.Chin J Exp Tradit Med Form，2022，28（24）：42-49.
  64. 64.
    YAN L K，WEN Y Y，LI Y J.Pharmaceutical research on Polyporus umbellatus in traditional Chinese medicine［J］.J Chin Med Mater，2023，46（6）：1557-1562.
  65. 65.
    LU W J，REN H，CUI X M，et al.Research progress on effective components，pharmacological mechanisms and clinical use of Polyporus umbellatus in diuresis-promotion and dampness-clearance［J］.China Pharm，2023，34（11）：1399-1403.
  66. 66.
    ZENG M N，LI M，ZHANG B B，et al.Comparison of the diuretic effects of descurainiae semen，coicis semen and plantaginis semen［J］.Chin Tradit Pat Med，2018，40（1）：40-46.
  67. 67.
    YANG J J.Clinical efficacy observation of Tinglizi Dazao Xiefei decoction combined with recombinant human brain natriuretic peptide in patients with chronic heart failure［J］.Pract Clin J Integr Tradit Chin West Med，2024，24（17）：99-102.
  68. 68.
    HAO X X，XIE S Y，WANG Y P，et al.Study on the diuretic effect of Tingli Dazao Xiefei decoction on rats with heart failure after myocardial infarction［J］.Lishizhen Med Mater Med Res，2022，33（12）：2882-2885.
  69. 69.
    ZHANG B C，LI X P，LI X P，et al.Discussion on Linggui Zhugan decoction in treating chronic heart failure by unblocking Xuanfu and regulating Qi transformation of Sanjiao［J］.China J Tradit Chin Med Pharm，2019，34（3）：1006-1008.
  70. 70.
    LI B X，LI G Y，PENG Y Z，et al.Effects of Linggui Zhugan decoction on cardiac function，levels of neuroendocrine factors，and NF-κB protein expression in cardiac tissue of rats with right heart failure induced by pulmonary hypertension［J］.J Chengdu Univ Tradit Chin Med，2021，44（2）：31-36.
  71. 71.
    ZHAO F，GAO Q，SHI L，et al.Efficacy of modified Xiaoqinglong decoction in the treatment of chronic heart failure and its impact on neuroendocrine and cytokines［J］.Prev Treat Cardiovasc Dis，2023，13（1）：35-38.
  72. 72.
    ZHU D W，DAI X H.A brief analysis of treating chronic heart failure from the perspectives of the heart and spleen［J］.Chin J Integr Med Cardio/Cerebrovasc Dis，2018，16（1）：105-107.
  73. 73.
    HUANG Q，DAI L，ZHANG X F.Clinical observation on treating heart failure from the aspect of spleen［J］.Guangming J Chin Med，2023，38（7）：1219-1222.
  74. 74.
    WU J，SONG N，LI N，et al.Effect of Xiangsha Liujunzi pill on myocardial endothelin receptor and angiotensin receptor's expression in spleen deficiency and phlegm turbidity syndrome rats［J］.Chin Arch Tradit Chin Med，2015，33（8）：1868-1871.
  75. 75.
    WENG H Z，ZHAO H Y，PENG Y，et al.Effect of modified Wuling powder on heart failure with preserved ejection fraction differentiated as Yang deficiency and blood stasis syndrome［J］.J Guangzhou Univ Tradit Chin Med，2020，37（7）：1207-1211.
  76. 76.
    GAO C，ZHANG Y，LIN H，et al.Clinical effect of modified Wuling powder combined with conventional western medicine on patients with chronic heart failure（Qi deficiency and blood stasis type）［J］.Chin Arch Tradit Chin Med，2023，41（2）：177-180.
  77. 77.
    XUE Y.Research on the application effect of Wuling powder in the treatment of chronic heart failure［J］.Cardiovasc Dis J Integr Tradit Chin West Med，2018，6（18）：91，93.
  78. 78.
    HE M Y，CONG Z F，WANG S G，et al.Review of chemical constituents，pharmacological effects and clinical applications of Zhenwu decoction and prediction and analysis of its Q-markers［J］.Chin Arch Tradit Chin Med，2022，40（2）：56-62.
  79. 79.
    GUO L L，PENG L，SHU H，et al.Effect of Zhenwu decoction on chronic heart failure due to yang deficiency and water flooding and its influence on levels of IL-1 and TNF-α［J］.Chin Arch Tradit Chin Med，2021，39（7）：192-195.
  80. 80.
    HONG L L，ZHANG S，WANG Q，et al.Effect of Zhenwu decoction on chronic heart failure rats based on RAAS/NF-κB/inflammatory factor cascade reaction［J］.Chin Tradit Herb Drugs，2020，51（5）：1279-1286.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website